The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews.

ABSTRACT:

Aims

To summarize reported cancer events associated with SGLT-2 inhibitors used in patients with type 2 diabetes mellitus, as well as assess the quality of included reviews.

Materials and methods

In May 2019, we searched PubMed, Embase and the Cochrane Library for quantitative systematic reviews assessing the safety of SGLT-2 inhibitors. Data were abstracted using a standardized form, and methodological quality was assessed using the AMSTAR 2 tool. Main outcome measures included total cancer events and specific cancers such as breast cancer, bladder cancer, gastrointestinal cancer, prostate cancer, respiratory cancer, renal cancer and skin cancer. Pooled treatment effects from included reviews were summarized for SGLT-2 inhibitors as a class and for individual SGLT-2 inhibit

SUBMITTER: Pelletier R 

PROVIDER: S-EPMC7375059 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature